Chemical and structural modifications enhance brain shuttle peptides for improved blood-brain barrier penetration

The blood-brain barrier (BBB) presents a formidable challenge for delivering therapeutics to the central nervous system (CNS) due to its highly selective permeability and robust enzymatic defense mechanisms. This barrier effectively protects the brain but simultaneously restricts the passage of most drugs, limiting treatment options for neurological disorders. Brain shuttle peptides offer a promising solution by leveraging receptor-mediated transcytosis to actively transport therapeutic payloads across the BBB, bypassing passive diffusion limitations and enzymatic degradation. Optimizing these peptides is crucial to enhance their pharmacokinetic properties and transcytosis efficiency, addressing a critical gap in CNS pharmacotherapy.

This comprehensive review systematically analyzed various chemical and structural optimization strategies employed to enhance the pharmacokinetic properties and transcytosis efficiency of brain shuttle peptides. It synthesized findings on diverse modifications, including cyclization, retro-enantio changes, and multivalent presentation, drawing examples from engineered peptides such as retro-D-THR, retro-D-T7, and BB4. The review also explored the potential of venom-derived scaffolds like MiniAp-4 and MiniCTX3, as well as dual-ligand systems like THR-TAT conjugates. The scope encompassed mechanisms for improving proteolytic resistance, preserving receptor affinity, and increasing cellular uptake to overcome the blood-brain barrier.

The review identified several key strategies for enhancing brain shuttle peptides. Cyclization and retro-enantio modifications were found to confer significant proteolytic resistance while effectively preserving receptor affinity, as exemplified by engineered peptides such as retro-D-THR, retro-D-T7, and BB4. Venom-derived scaffolds, including MiniAp-4 and MiniCTX3, were highlighted for their inherent potential in BBB penetration. Multivalent presentation, achieved through branched architectures or nanoparticle surface functionalization, was shown to significantly increase avidity and cellular uptake, thereby improving transcytosis efficiency. Dual-ligand systems, specifically THR-TAT conjugates, demonstrated synergistic effects in glioma models, enhancing both BBB crossing and tumor targeting. While PEGylation is a common strategy for prolonging circulation and reducing immunogenicity in drug delivery, its application in brain shuttle systems remains limited due to potential interference with the crucial receptor-mediated uptake mechanism. These collective advances underscore the versatility of protease-resistant brain shuttle peptides as targeted delivery vehicles.